Development and application of a biomarker assay for determining the pharmacodynamic activity of an antagonist candidate biotherapeutic antibody to IL21R in whole blood

Journal of Translational Medicine

Volumn 8, Issue , 2010, Pages

  Arai, Maya ^a   Jain, Sadhana ^a   Weaver, Amy A ^a   Hill, Andrew A ^a   Guo, Yongjing ^a   Bree, Andrea G ^a   Smith Jr, Michael F ^b   Allen, Scott W ^a   LaVallie, Edward R ^a   Young, Deborah ^a   Bloom, Laird ^a   Adkins, Karissa ^c   O'Toole, Margot ^a  

^a PFIZER INC   (United States)

^b Translational Medicine Inflammation   (United States)

^c Drug Safety Research and Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AB 01 ANTIBODY; BIOLOGICAL MARKER; CD19 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 21; INTERLEUKIN 21 RECEPTOR; INTERLEUKIN 6; PROTEIN ANTIBODY; RECOMBINANT CYTOKINE; RNA; UNCLASSIFIED DRUG; ANTIBODY; INTERLEUKIN DERIVATIVE;

ADULT ANIMAL; ANIMAL EXPERIMENT; ARTICLE; BIOASSAY; BLOOD SAMPLING; CONTROLLED STUDY; CROSS LINKING; DRUG SAFETY; EX VIVO STUDY; GENE EXPRESSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MONKEY; NONHUMAN; PHARMACODYNAMICS; PHARMACOLOGICAL BLOCKING; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SIGNAL TRANSDUCTION; STIMULATION; ANIMAL; BLOOD; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; IMMUNOLOGY; MACACA; METHODOLOGY; TIME; TITRIMETRY;

ANIMALS; ANTIBODIES; BIOLOGICAL ASSAY; BIOLOGICAL MARKERS; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKINS; MACACA FASCICULARIS; RECEPTORS, INTERLEUKIN-21; SIGNAL TRANSDUCTION; TIME FACTORS; TITRIMETRY;

EID: 77952724378     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-8-51     Document Type: Article

References (22)

1. Kuhlmann J, Wensing G. The applications of biomarkers in early clinical drug development to improve decision-making processes. Curr Clin Pharmacol 2006, 1:185-191. 10.2174/157488406776872578, 18666370.
2. Guidance for Industry Dosage and Administration Section of Labeling for Human Prescription Drug and Biological Products. , http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryIn formation/Guidances/UCM075066.pdf
3. Danhof M, de Lange EC, Della Pasqua OE, Ploeger BA, Voskuyl RA. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends Pharmacol Sci 2008, 29:186-191. 10.1016/j.tips.2008.01.007, 18353445.
4. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat Rev Drug Discov 2004, 3:711-715. 10.1038/nrd1470, 15286737.
5. Lavallie ER, Dorner AJ, Burczynski ME. Use of ex vivo systems for biomarker discovery. Curr Opin Pharmacol 2008, 8:647-653. 10.1016/j.coph.2008.08.003, 18771752.
6. Ray CA, Dumaual C, Willey M, Fill J, O'Brien PJ, Gourley I, Devanarayan V, Konrad RJ. Optimization of analytical and pre-analytical variables associated with an ex vivo cytokine secretion assay. J Pharm Biomed Anal 2006, 41:189-195. 10.1016/j.jpba.2005.10.013, 16321496.
7. Parasrampuria DA, de Boer P, Desai-Krieger D, Chow AT, Jones CR. Single-dose pharmacokinetics and pharmacodynamics of RWJ 67657, a specific p38 mitogen-activated protein kinase inhibitor: a first-in-human study. J Clin Pharmacol 2003, 43:406-413. 10.1177/0091270002250615, 12723461.
8. Vugmeyster Y, Guay H, Szklut P, Qian MD, Jin M, Widom A, Spaulding V, Bennett F, Lowe L, Andreyeva T, Lowe D, Lane S, Thom G, Valge-Archer V, Gill D, Young D, Bloom L. In vitro potency, pharmacokinetic profiles, and pharmacological activity of optimized anti-IL-21R antibodies in a mouse model of lupus. MAbs 2010, 2:335-346.
9. Black R, Ekman L, Lieberburg I, Grundman M, Callaway J, Gregg KM, Jacobsen JS, Gill D, Tchistiakova L, Windom A. Immunotherapy regimes dependent on APOE status, patent application number 20090155256. 2009, , http://appft.uspto.gov
10. Kasaian MT, Tan XY, Jin M, Fitz L, Marquette K, Wood N, Cook TA, Lee J, Widom A, Agostinelli R, Bree A, Schlerman FJ, Olland S, Wadanoli M, Sypek J, Gill D, Goldman SJ, Tchistiakova L. Interleukin-13 neutralization by two distinct receptor blocking mechanisms reduces immunoglobulin E responses and lung inflammation in cynomolgus monkeys. J Pharmacol Exp Ther 2008, 325:882-892. 10.1124/jpet.108.136515, 18337474.
11. Schroeder A, Mueller O, Stocker S, Salowsky R, Leiber M, Gassmann M, Lightfoot S, Menzel W, Granzow M, Ragg T. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol 2006, 7:3. 10.1186/1471-2199-7-3, 1413964, 16448564.
12. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408. 10.1006/meth.2001.1262, 11846609.
13. Vugmeyster Y, Allen S, Szklut P, Bree A, Ryan M, Ma M, Spaulding V, Young D, Guay H, Bloom L, Leach MW, O'Toole M, Adkins K. Correlation of pharmacodynamic activity, pharmacokinetics, and anti-product antibody responses to anti-IL-21R antibody therapeutics following IV administration to cynomolgus monkeys. J Transl Med 2010, 8:41. 10.1186/1479-5876-8-41, 20420683.
14. Guo Y, Hill A, Ramsey R, Immermann F, Corcoran C, Young D, LaVallie E, Pfeifer R, Warner G, Bologna M, Bloom L, O'Toole M. Assessing agonistic potential of a candidate therapeutic anti-IL21R antibody. J Transl Med 2010, 8:50. 10.1186/1479-5876-8-50, 20504348.
15. O'Toole M, Legault H, Ramsey R, Wynn TA, Kasaian MT. A novel and sensitive ELISA reveals that the soluble form of IL-13R-alpha2 is not expressed in plasma of healthy or asthmatic subjects. Clin Exp Allergy 2008, 38:594-601. 10.1111/j.1365-2222.2007.02921.x, 2693895, 18307523.
16. Caruso R, Fina D, Peluso I, Stolfi C, Fantini MC, Gioia V, Caprioli F, Del Vecchio Blanco G, Paoluzi OA, Macdonald TT, Pallone F, Monteleone G. A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3alpha, by gut epithelial cells. Gastroenterology 2007, 132:166-175. 10.1053/j.gastro.2006.09.053, 17241869.
17. Monteleone G, Caruso R, Fina D, Peluso I, Gioia V, Stolfi C, Fantini MC, Caprioli F, Tersigni R, Alessandroni L, MacDonald TT, Pallone F. Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21. Gut 2006, 55:1774-1780. 10.1136/gut.2006.093187, 1856468, 16682426.
18. Jungel A, Distler JH, Kurowska-Stolarska M, Seemayer CA, Seibl R, Forster A, Michel BA, Gay RE, Emmrich F, Gay S, Distler O. Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis. Arthritis Rheum 2004, 50:1468-1476. 10.1002/art.20218, 15146416.
19. Leonard WJ, Spolski R. Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation. Nat Rev Immunol 2005, 5:688-698. 10.1038/nri1688, 16138102.
20. Zeng R, Spolski R, Finkelstein SE, Oh S, Kovanen PE, Hinrichs CS, Pise-Masison CA, Radonovich MF, Brady JN, Restifo NP, Berzofsky JA, Leonard WJ. Synergy of IL-21 and IL-15 in regulating CD8 + T cell expansion and function. J Exp Med 2005, 201:139-148. 10.1084/jem.20041057, 2212766, 15630141.
21. Strengell M, Sareneva T, Foster D, Julkunen I, Matikainen S. IL-21 up-regulates the expression of genes associated with innate immunity and Th1 response. J Immunol 2002, 169:3600-3605.
22. Ettinger R, Kuchen S, Lipsky PE. The role of IL-21 in regulating B-cell function in health and disease. Immunol Rev 2008, 223:60-86. 10.1111/j.1600-065X.2008.00631.x, 18613830.